Advertisement

 

 

The Efficacy and Safety of Miconazole Nitrate Mucoadhesive Tablets versus Itraconazole Capsules in the Treatment of Oral Candidiasis: An Open-Label, Randomized, Multicenter Trial.

The Efficacy and Safety of Miconazole Nitrate Mucoadhesive Tablets versus Itraconazole Capsules in the Treatment of Oral Candidiasis: An Open-Label, Randomized, Multicenter Trial.
Author Information (click to view)

Yan Z, Liu X, Liu Y, Han Y, Lin M, Wang W, Guan X, Zhu S, Zhang H, Wang Q, Chou L, Zhu X, Hua H,


Yan Z, Liu X, Liu Y, Han Y, Lin M, Wang W, Guan X, Zhu S, Zhang H, Wang Q, Chou L, Zhu X, Hua H, (click to view)

Yan Z, Liu X, Liu Y, Han Y, Lin M, Wang W, Guan X, Zhu S, Zhang H, Wang Q, Chou L, Zhu X, Hua H,

Advertisement
Share on FacebookTweet about this on TwitterShare on LinkedIn

PloS one 2016 12 1511(12) e0167880 doi 10.1371/journal.pone.0167880

Abstract
BACKGROUND
Oral candidiasis (OC) is a common oral fungal infection. Recently, miconazole mucoadhesive tablets have been gaining attention for OC treatment. Despite trials in patients with human immunodeficiency virus and cancer, evidence of its application in the large-scale, general population with OC is lacking. This study aimed to evaluate the efficacy and safety of miconazole nitrate mucoadhesive tablets in comparison with itraconazole capsules for OC treatment.

METHODS
The study was a randomized, open-label, parallel-armed, multicenter clinical trial. Totally, 343 patients diagnosed with OC, who met the inclusion criteria, were randomly assigned to either a treatment group that received miconazole nitrate mucoadhesive tablets (10 mg) once daily or a control group that received itraconazole capsules (100 mg QD) for 2 weeks, and were followed up for 2 weeks. The clinical cure, improvement of clinical symptoms/signs, mycologic cure, and safety were evaluated.

RESULTS
The mucoadhesive tablets (n = 171) did not show inferiority to itraconazole (n = 172) in the treatment of OC. At the end of the 14-day treatment, the clinical cure rates were 45.29% and 41.76% in the miconazole and itraconazole groups, respectively (P = 0.3472). At the end of the 14-day follow-up, the clinical cure rates were 51.18% and 41.76% in the miconazole and itraconazole groups, respectively (P = 0.0329). Adverse events occurred in 53 subjects (33 in the miconazole group and 20 in the itraconazole group). There was no statistical difference in the safety profile between miconazole and itraconazole (P = 0.0533). Thrombocytopenic purpura, although rare, occurred in one patient in the miconazole group and was considered a drug-related, severe adverse event.

CONCLUSION
Miconazole nitrate mucoadhesive tablets may be as effective as systemic itraconazole capsule for OC treatment. Physicians should be cautious about thrombocytopenic purpura occurring as a rare and serious adverse event of miconazole nitrate.

TRIAL REGISTRATION
Chinese Clinical Trial Register ChiCTR-TRC-13003935.

Submit a Comment

Your email address will not be published. Required fields are marked *

twenty − fourteen =

[ HIDE/SHOW ]